Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 12:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 4,019 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome
Interventions: ATRN-119, Decitabine; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Multiple Sclerosis
Interventions: Frexalimab, MRI contrast-enhancing preparations; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 34
States / cities: Cullman, Alabama • Homewood, Alabama • Phoenix, Arizona + 29 more

Conditions: Breast Cancer Female
Interventions: Supervised Exercise, Home-based Exercise, Reduced Energy Diet, Group Phone Calls; Behavioral
Lead sponsor: Carol Fabian, MD; Other
Eligibility: 50 Years to 70 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Venous Thromboembolism (VTE)
Interventions: REGN7508, Apixaban; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 3
States / cities: Hialeah, Florida • New York, New York • El Paso, Texas

Conditions: Breast Cancer, Breast Cancer Female, Breast Adenocarcinoma
Interventions: Standard of Care Schedule Variation: SABR, Breast-conserving Surgery; Other · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 50 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Nonalcoholic Fatty Liver Disease
Interventions: CB4211 Dose 1, CB4211 Dose 2, CB4211 Dose 3, CB4211 Dose 4, CB4211 Dose 5, CB4211 Dose 6, CB4211 Dose TBD, Placebo; Drug
Lead sponsor: CohBar, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 4
States / cities: Chula Vista, California • Dallas, Texas • San Antonio, Texas

Conditions: Non Small Cell Lung Cancer
Interventions: Calcitriol; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 4
States / cities: Ann Arbor, Michigan • Buffalo, New York

Conditions: Healthy Volunteers
Interventions: DNL201, Placebo; Drug
Lead sponsor: Denali Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Diabetes
Interventions: Diabetes self management workbook; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Multiple Myeloma
Interventions: Carfilzomib, Venetoclax, Dexamethasone; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 18
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Hollywood, Florida + 15 more

Conditions: Air Trapping, Emphysema, Hyperinflation
Interventions: Hyperpolarized Xenon MRI, Apreo BREATHE Airway Scaffold; Drug · Device
Lead sponsor: Apreo Health, Inc.; Industry
Eligibility: 40 Years to 84 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Birmingham, Alabama • Kansas City, Kansas

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: cancer prevention intervention, educational intervention; Procedure
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 20 Years
Enrollment: 2,242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 19
States / cities: Long Beach, California • Farmington, Connecticut • Fort Myers, Florida + 16 more

Conditions: Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus (SLE), Dermatomyositis (DM), Systemic Sclerosis (SSc)
Interventions: LMY-922; Biological
Lead sponsor: Luminary Therapeutics; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Questionnaires, Electroencephalography (EEG), Magnetic Resonance Imaging (fMRI, Meditation Classes; Behavioral · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 35 Years to 65 Years · Female only
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Normal Healthy
Interventions: PF-05221304, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Solid Tumor
Interventions: LY3405105; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 7
States / cities: Fayetteville, Arkansas • New Haven, Connecticut • New York, New York + 3 more

Conditions: Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
Interventions: Digital self-management program, Standard Care; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Cystic Fibrosis
Interventions: VX-121/TEZ/D-IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 1 Year to 11 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 19
States / cities: Orange, California • Palo Alto, California • Aurora, Colorado + 16 more

Conditions: Lung Cancer, Tobacco Use
Interventions: Community health worker delivered outreach, shared decision-making, tobacco treatment, and navigation, Lay Navigator delivered outreach, shared decision-making, tobacco treatment, and navigation, Enhanced Usual Care; Behavioral · Other
Lead sponsor: Baystate Medical Center; Other
Eligibility: 50 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Springfield, Massachusetts

Conditions: Amyotrophic Lateral Sclerosis (ALS), Parkinson's Disease (PD)
Interventions: The MIND diet; Behavioral
Lead sponsor: The University of Tennessee, Knoxville; Other
Eligibility: 30 Years and older
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Elizabethton, Tennessee • Knoxville, Tennessee

Conditions: Functional Constipation (FC), Chronic Idiopathic Constipation (CIC)
Interventions: Placebo for Linaclotide, Linaclotide; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 2 Years to 5 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 38
States / cities: Foley, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 33 more

Conditions: SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus
Interventions: mRNA-1273, mRNA-1010, mRNA-1345, FLUAD®, mRNA-1647; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 308 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 8
States / cities: Hollywood, Florida • Savannah, Georgia • Sioux City, Iowa + 4 more

Conditions: Suicide, Attempted, Suicidal Ideation
Interventions: Brief Cognitive Behavioral Therapy (BCBT), Present-Centered Therapy (PCT), Treatment as Usual (TAU); Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 3
States / cities: Jacksonville, North Carolina • Columbus, Ohio • Charleston, South Carolina

Conditions: Diabetes Mellitus, Type 2, Cardiovascular Diseases
Interventions: Canagliflozin, Empagliflozin, Dapagliflozin, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-like Peptide-1 (GLP-1) Agonist, Anti-hyperglycemic Agents (AHA), Thiazolidinediones (TZD), Sulfonylureas (SU), Insulin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: Not listed
Enrollment: 714,582 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Titusville, New Jersey

Search by objective public record fields.

ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS

Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

High Physical Activity During a Weight Loss Intervention for Breast Cancer Survivors and High Risk Women

Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers

Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer

A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease

Phase I/II Calcitriol in Lung Cancer

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Healthy Volunteers

I Can Do This! Managing My Diabetes

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

Xenon MRI to Evaluate Changes to Lung Function Following Bronchoscopic Treatment of Air Trapping in Emphysema

Registration and Informed Consent Study for the Childhood Cancer Research Network

BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease

Effects of Meditation on Cognitive Function and Quality of Life

Single Dose, Repeated Dose, and Conditional Food Effect Study of PF-05221304 in Healthy Subjects

A Study of LY3405105 in Participants With Advanced Cancer

Developing a Self-Management Intervention to Improve Health Outcomes for Patients With Inflammatory Bowel Disease

Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age

A Community Health Intervention to Improve Lung Cancer Screening Uptake in Community Health Centers

The Meals Study for Amyotrophic Lateral Sclerosis and Parkinson's Disease

A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation

A Study of Modified mRNA Vaccines in Healthy Adults

Brief Cognitive Behavioral Therapy Replication Trial

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease